| Theme | Novel therapeutic strategy for ulcerative colitis | |
|---|---|---|
| Title | The possibility of novel treatment in patients with ulcerative colitis | |
| Publish Date | 2013/03 | |
| Author | Kenji Watanabe | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Noriko Kamata | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Mitsue Sogawa | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Tetsuya Tanigawa | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Hirokazu Yamagami | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Kazunari Tominaga | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Toshio Watanabe | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Yasuhiro Fujiwara | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Tetsuo Arakawa | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| [ Summary ] | A higher number of treatment options are available for treatment of ulcerative colitis in Japan than elsewhere in the world. However, some of these cases are considered to be intractable. The approval of new antiTNF-α agents is expected to occur in Japan. The use of antiTNF-α biosimilars is an emerging issue. Novel drugs for α4 integlin or JAK3 treatment are being developed in global clinical trials. Collaboration and changes in drug development continue in Japan to close the gap in treatment options compared to those available in the West. | |